Home›Trial›NCT05943535
🔬NCT05943535Phase 3RECRUITING

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Study Summary

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

Conditions
Progressive Pulmonary FibrosisInterstitial Lung Disease
Interventions / Drugs
PlaceboInhaled TreprostinilTreprostinil Ultrasonic Nebulizer
View on ClinicalTrials.gov ↗
Sponsor
UTHR
United Therapeutics
Pulmonary
F35/100
Study Details
Enrollment698 participants
Primary Completion—
Lead SponsorUnited Therapeutics
Data Retrieved2026-04-11 04:30:42.432923+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.